Trazodone in late life depressive states: a double-blind multicenter study versus amitriptyline and mianserin

A. C. Altamura, M. C. Mauri, F. Colacurcio, P. L. Scapicchio, C. Hadjchristos, G. Carucci, M. Minervini, R. Montanini, M. Perini, N. Rudas, B. Carpiniello, A. D'Aloise, A. Malinconico

Research output: Contribution to journalArticlepeer-review

Abstract

Seventy five elderly depressed in-patients, ages ranging from 60 to 83 years, diagnosed as Major Depression according to DSM III were treated, under double-blind conditions, with 75 mg Amitriptyline (AMI) (26 patients), 60 mg Mianserin (MIA) (24 patients) or 150 mg Trazodone (TRZ) (25 patients) p.o. for 5 weeks. There were no differences in the clinical outcome between the three groups of patients at the end of the trial, with a significant amelioration (P

Original languageEnglish
JournalPsychopharmacology
Volume95
Issue number1
DOIs
Publication statusPublished - Mar 1988

Keywords

  • Amitriptyline
  • Elderly
  • Major depression
  • Mianserin
  • Trazodone

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Trazodone in late life depressive states: a double-blind multicenter study versus amitriptyline and mianserin'. Together they form a unique fingerprint.

Cite this